Predictors of long-acting injectable antipsychotic prescription at discharge in patients with schizophrenia and other psychotic disorders
International Clinical Psychopharmacology Aug 07, 2021
Sahin OS, Mursalova Z, Gadimov S, et al. - The data indicated that long-acting injectable antipsychotics (LAIs) are applied at a high rate; nevertheless, they are still initiated at a later stage, mostly in chronic patients with a lack of insight and compliance at admission.
Researchers designed a retrospective study including a total of 400 inpatients.
They obtained sociodemographic and clinical characteristics of the patients, the treatments applied in the past and prescribed at discharge from the hospitalization files.
They matched these characteristics of those who were given LAI treatment at discharge to the patients who were given oral treatments.
At discharge, 39% of the patients have been prescribed an LAI.
It was shown that the duration of illness was longer, and the number of previous hospitalizations was higher in the LAI group.
In logistic regression analysis, the findings demonstrated that the nonadherence to the antipsychotics before the hospitalization, the previous history of LAI use, lack of insight at the admission, and no previous antidepressant use were found as independent contributors to LAI prescription as the treatment of discharge.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries